Literature DB >> 2475702

Interaction of selected vasodilating beta-blockers with adrenergic receptors in human cardiovascular tissues.

A Monopoli1, A Forlani, M Bevilacqua, T Vago, G Norbiato, P Bertora, P Biglioli, F Alamanni, E Ongini.   

Abstract

beta- And alpha 1-adrenoceptor antagonist properties of bufuralol, carvedilol, celiprolol, dilevalol, labetalol, and pindolol were investigated in human myocardium and mammary artery using binding techniques and functional studies. In myocardial membranes, beta-adrenoceptor antagonists showed monophasic competition isotherms for [125I]pindolol binding with high affinity (Ki from 1-100 nM), except for celiprolol which displayed a biphasic competition isotherm (pKi = 6.4 +/- 0.06 for beta 1- and 4.8 +/- 0.07 for beta 2-adrenoceptors). Drug interactions with alpha 1-adrenoceptors were evaluated in human mammary artery by [3H]prazosin binding and by measuring contractile responses to norepinephrine (NE). Labetalol and carvedilol showed a moderate affinity for alpha 1-adrenoceptors (pKi = 6.2 +/- 0.01 and 6.1 +/- 0.06, respectively), and inhibited NE-induced contractions (pA2 = 6.93 +/- 0.23 and 8.64 +/- 0.24, respectively). Dilevalol, bufuralol, and pindolol displayed weak effect both in binding (Ki in micromolar range) and functional experiments (pA2 = 5.98, 5.54, and 6.23, respectively). Celiprolol did not show antagonist properties up to 100 microM in functional studies, but displayed a slight affinity for alpha 1-adrenoceptors in binding studies. The data indicate that the vasodilating activity of these beta-adrenoceptor antagonists is caused in some instances by an alpha 1-adrenoceptor antagonism (labetalol, carvedilol), whereas for the others alternative mechanisms should be considered.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2475702     DOI: 10.1097/00005344-198907000-00020

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  8 in total

1.  Does treatment with beta-adrenergic blocking agents cause a decrease in beta 2-adrenoceptor affinity?

Authors:  W M Blankesteijn; S J Graafsma; M P Hectors; E A Olde Riekerink; J F Rodrigues de Miranda; T Thien
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  C J Dunn; A P Lea; A J Wagstaff
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 3.  Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.

Authors:  R J Milne; M M Buckley
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

Review 4.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

5.  Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes.

Authors:  M R Bristow; P Larrabee; B Müller-Beckmann; W Minobe; R Roden; L Skerl; J Klein; D Handwerger; J D Port
Journal:  Clin Investig       Date:  1992

6.  Celiprolol exerts microvascular dilatation by activation of beta 2-adrenoceptors.

Authors:  S Dhein; S Titzer; M Wallstein; A Müller; R Gerwin; B Panzner; W Klaus
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

7.  Clinical pharmacology of carvedilol.

Authors:  B Tomlinson; B N Prichard; B R Graham; R J Walden
Journal:  Clin Investig       Date:  1992

8.  5-Hydroxytryptamine induces contraction in isolated human mammary artery: effect of ketanserin.

Authors:  A Monopoli; A Conti; A Forlani; E Ongini; C Antona; P Biglioli
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.